September 9, 2024 08:58 AM EDTUpdated 03:53 PM

Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer, bispecific combo strategy

Lei Lei Wu

News Reporter

Mid-stage clinical trial results show why Merck and Daiichi Sankyo recently moved an antibody-drug conjugate from their $4 billion partnership into Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer, bispecific combo strategy

Lei Lei Wu

News Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Mer­ck, Dai­ichi Sankyo de­tail Phase 2 ADC re­sults in small cell lung can­cer, bis­pe­cif­ic com­bo strat­e­gy

Lei Lei Wu

News Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer, bispecific combo strategy

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?